bevacizumab,panitumumab
takeda,amgen,roche
[]
 absence of gene alterations (-ve hyperselection) in ctdna predicts benefit from pani rather than sideness! are we excluding pts from egfri with sidedness alone more to come &amp; validation studies needed a biomarker study of the phase iii paradigm trial #gi23 #crcsm 
Medical Oncologist; clinical and translational researcher pancreatic and hepatobiliary cancers. Views are my own